ATP-sensitive inward rectifier potassium channel 11

Description:

Description
  • Accession: Q14654
  • Swissprot: KCJ11_HUMAN
  • Organism: Homo sapiens
  • Gene: KCNJ11
  • Target class: Ion channel

Drug Relations:

acetohexamide
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Bioactivity details MOA
carbutamide
A sulfonylurea antidiabetic agent with similar actions and uses to CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277) Bioactivity details MOA
chlorpropamide
A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277) Bioactivity details MOA
diazoxide
A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group. Bioactivity details MOA
glibenclamide
An antidiabetic sulfonylurea derivative with actions similar to those of chlorpropamide. Bioactivity details MOA
glibornuride
was MH 1975-92 (see under SULFONYLUREA COMPOUNDS 1975-90); use SULFONYLUREA COMPOUNDS to search GLIBORNURIDE 1975-92; an oral, sulfonylurea hypoglycemic agent which stimulates insulin secretion Bioactivity details MOA
gliclazide
An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion. Bioactivity details MOA
glimepiride
Bioactivity details MOA
glipizide
An oral hypoglycemic agent which is rapidly absorbed and completely metabolized. Bioactivity details MOA
gliquidone
Bioactivity details MOA
glisoxepide
oral sulfonylurea hypoglycemic agent which stimulates insulin secretion; minor descriptor (75-85); on-line & Index Medicus search SULFONYLUREA COMPOUNDS (75-85); RN given refers to parent cpd Bioactivity details MOA
minoxidil
A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371) Bioactivity details MOA
mitiglinide
a rapid and short-acting hypoglycemic agent; acts on sulfonylurea receptor closing KATP channels; considered one of the glinides-an imprecise grouping; structure given in first source Bioactivity details MOA
nateglinide
A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES. Bioactivity details MOA
pinacidil
A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed) Bioactivity details MOA
repaglinide
Bioactivity details MOA
tolazamide
A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. Bioactivity details MOA
tolbutamide
A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290) Bioactivity details MOA
cibenzoline
Bioactivity details MOA
levosimendan
A hydrazone and pyridazine derivative; the levo-form is a phosphodiesterase III inhibitor, calcium-sensitizing agent, and inotropic agent that is used in the treatment of HEART FAILURE. Bioactivity details MOA
nicorandil
A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase. Bioactivity details MOA
propafenone
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. Bioactivity details MOA